CY1125017T1 - Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho - Google Patents

Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho

Info

Publication number
CY1125017T1
CY1125017T1 CY20221100132T CY221100132T CY1125017T1 CY 1125017 T1 CY1125017 T1 CY 1125017T1 CY 20221100132 T CY20221100132 T CY 20221100132T CY 221100132 T CY221100132 T CY 221100132T CY 1125017 T1 CY1125017 T1 CY 1125017T1
Authority
CY
Cyprus
Prior art keywords
rho
protein kinase
heterocylamino
regulators
related protein
Prior art date
Application number
CY20221100132T
Other languages
English (en)
Inventor
Clifford D. JONES
Peter BUNYARD
Gary Pitt
Liam BYRNE
Thomas Pesnot
Nicolas E.S. GUISOT
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of CY1125017T1 publication Critical patent/CY1125017T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Η παρούσα εφεύρεση αναφέρεται σε νέες ενώσεις και φαρμακευτικές συνθέσεις που περιλαμβάνουν ενώσεις της εφεύρεσης χρήσιμες ως ρυθμιστές της πρωτεϊνικής κινάσης που σχετίζεται με τη Rho (ROCK), για παράδειγμα αναστολείς της ROCK1 και/ή της ROCK2. Μέθοδοι θεραπείας που χρησιμοποιούν τις ενώσεις προβλέπονται επίσης από την παρούσα εφεύρεση. Οι ενώσεις της εφεύρεσης είναι χρήσιμες στη θεραπεία ασθενειών που προκαλούνται από τη ROCK.
CY20221100132T 2018-01-25 2022-02-16 Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho CY1125017T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1801226.0A GB201801226D0 (en) 2018-01-25 2018-01-25 Modulators of Rho-associated protein kinase
PCT/GB2019/050215 WO2019145729A1 (en) 2018-01-25 2019-01-25 Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase

Publications (1)

Publication Number Publication Date
CY1125017T1 true CY1125017T1 (el) 2023-03-24

Family

ID=61558335

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100132T CY1125017T1 (el) 2018-01-25 2022-02-16 Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho

Country Status (25)

Country Link
US (2) US11497751B2 (el)
EP (2) EP3743420B1 (el)
JP (2) JP2021512158A (el)
KR (1) KR20200113216A (el)
CN (1) CN111655681B (el)
AU (1) AU2019213214B2 (el)
BR (1) BR112020013759A2 (el)
CA (1) CA3088330A1 (el)
CY (1) CY1125017T1 (el)
DK (1) DK3743420T3 (el)
EA (1) EA202091711A1 (el)
ES (1) ES2907833T3 (el)
GB (1) GB201801226D0 (el)
HR (1) HRP20220269T8 (el)
HU (1) HUE058940T2 (el)
IL (1) IL275988B2 (el)
LT (1) LT3743420T (el)
MX (1) MX2020007898A (el)
PH (1) PH12020550986A1 (el)
PL (1) PL3743420T3 (el)
PT (1) PT3743420T (el)
SG (1) SG11202006087UA (el)
SI (1) SI3743420T1 (el)
WO (1) WO2019145729A1 (el)
ZA (1) ZA202003983B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN111718310B (zh) * 2019-08-19 2021-06-11 中国药科大学 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物
CN110845410B (zh) * 2019-10-29 2021-02-26 暨明医药科技（苏州）有限公司 一种一锅法制备6,7-二甲氧基-3,4-二氢异喹啉盐酸盐的方法
IL310209A (en) * 2021-07-26 2024-03-01 Harvard College ROCK2 inhibitors and their uses
CN113999211B (zh) * 2021-11-23 2022-11-29 郑州大学 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物
GB202200735D0 (en) * 2022-01-20 2022-03-09 Redx Pharma Plc Compounds
WO2023182856A1 (ko) * 2022-03-24 2023-09-28 서울대학교산학협력단 로-키나제 억제제를 포함하는 켈로이드 등 피부 섬유화 질환의 예방 또는 치료용 약학적 조성물 및 그의 용도
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207396D0 (en) 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
CA2422371C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
WO2004052280A2 (en) * 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
EP1730124A4 (en) * 2004-03-26 2009-04-01 Amphora Discovery Corp Certain compounds based on triazole, compositions and applications thereof
WO2006135383A2 (en) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
TW200804314A (en) * 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
JP2011525892A (ja) * 2008-06-18 2011-09-29 メルク・シャープ・エンド・ドーム・コーポレイション Ｊａｎｕｓキナーゼの阻害剤
WO2011119894A2 (en) * 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
RS55165B1 (sr) * 2010-12-20 2017-01-31 Merck Serono Sa Indazolil triazol derivati kao irak inhibitori
US20150011751A1 (en) * 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
WO2016138335A1 (en) * 2015-02-27 2016-09-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
PE20220507A1 (es) 2015-12-16 2022-04-07 Loxo Oncology Inc Compuestos utiles como inhibidores de cinasa
JP7039802B2 (ja) * 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase

Also Published As

Publication number Publication date
AU2019213214A1 (en) 2020-07-09
IL275988B1 (en) 2023-03-01
WO2019145729A9 (en) 2020-07-30
JP2021512158A (ja) 2021-05-13
PT3743420T (pt) 2022-02-04
ES2907833T3 (es) 2022-04-26
IL275988B2 (en) 2023-07-01
EP4026834A1 (en) 2022-07-13
US11497751B2 (en) 2022-11-15
US20210038606A1 (en) 2021-02-11
KR20200113216A (ko) 2020-10-06
JP2024026193A (ja) 2024-02-28
EA202091711A1 (ru) 2020-10-20
MX2020007898A (es) 2020-09-07
CN111655681A (zh) 2020-09-11
WO2019145729A1 (en) 2019-08-01
LT3743420T (lt) 2022-02-25
US20230021916A1 (en) 2023-01-26
HUE058940T2 (hu) 2022-09-28
EP3743420A1 (en) 2020-12-02
CA3088330A1 (en) 2019-08-01
SI3743420T1 (sl) 2022-06-30
IL275988A (en) 2020-08-31
PL3743420T3 (pl) 2022-03-21
HRP20220269T8 (hr) 2022-12-09
CN111655681B (zh) 2024-01-05
AU2019213214B2 (en) 2023-06-29
DK3743420T3 (da) 2022-03-07
EP3743420B1 (en) 2021-12-15
HRP20220269T1 (hr) 2022-05-13
SG11202006087UA (en) 2020-08-28
GB201801226D0 (en) 2018-03-14
PH12020550986A1 (en) 2021-03-22
BR112020013759A2 (pt) 2020-12-01
US11878020B2 (en) 2024-01-23
ZA202003983B (en) 2023-07-26

Similar Documents

Publication Publication Date Title
CY1125017T1 (el) Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho
CY1126132T1 (el) Πυριδαζινονες ως αναστολεις parp7
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CY1124478T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret
CY1123663T1 (el) Πυριμιδινονες ως αναστολεις τελεστη χια
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1122886T1 (el) Αναστολεις βρωμοεπικρατειων
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
CY1124918T1 (el) Ρυθμιστες ccr2
CY1119165T1 (el) Παραγωγα βενζιμιδαζολονης ως αναστολεις βρωμοπεδιου
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
CY1117595T1 (el) Πυραζολο-κιναζολινες ως ρυθμιστες δραστικοτητας της πρωτεϊνικης κινασης
BR112018072168A2 (pt) compostos derivados da pirimidina como inibidores da quinase jak
EA202090572A1 (ru) ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ
CY1122364T1 (el) Αναστολεις της ezh2
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CY1122957T1 (el) 1η-πυραζολο[4,3-β]πυριδινες ως αναστολεις ρdε1
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
CY1121334T1 (el) Αναστολεας κινασης aurora a